US-listed pharmaceutical company Horizon Therapeutics has hired Scott Brun, former head of corporate venturing unit AbbVie Ventures, as an adviser to its research and development leadership team.
Brun joined pharmaceutical firm AbbVie as vice-president of pharmaceutical development in 2012 when it spun off from Abbott Laboratories, where he had been since 2002.
Brun took the reins at AbbVie Ventures in four years later while also being named AbbVie’s vice-president of scientific affairs, and made GCV’s 2018 Powerlist before departing in April 2019.
Companies that received funding from AbbVie Ventures during Brun’s time in charge included immuno-neurology drug developer Alector, gene therapy developer Prevail Therapeutics and integrin therapeutics developer Morphic Holding, all of which have gone public in the past year.
